2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 217

Keeping a Balance: Social Engagement and Care Giving
Abstract Number: 1015

Key Genes and Pathways between Rheumatoid Arthritis and Osteoarthritis By Integrative Genome-Wide Gene Expression Profiling Analysis
Abstract Number: 2757

Kidney and Skin Single-Cell RNA Sequencing in Lupus Nephritis Provides Mechanistic Insights and Novel Potential Biomarkers
Abstract Number: 194

Kinesiophobia Moderates the Association between Anxiety and Disability in Chronic Low Back Pain
Abstract Number: 936

Knee Confidence Trajectories over 8 Years and Factors Associated with Poor Trajectories: Data from the Osteoarthritis Initiative
Abstract Number: 2993

Knee Joint Sounds: A Non-Invasive Modality for Classifying Knee Joint Health in Juvenile Idiopathic Arthritis
Abstract Number: 2414

Knowledge and Adherence to Current Immunization Recommendations in Patients with Rheumatoid Arthritis in Mexico
Abstract Number: 2317

Knowledge Translation in Juvenile Idiopathic Arthritis in Canada: A Focus on Parents of Children with JIA
Abstract Number: 2262

Knowledge, Beliefs and Concerns about Osteoporosis – a Qualitative Synthesis
Abstract Number: 2559

KZR-616, a Selective Inhibitor of the Immunoproteasome, Blocks the Disease Progression in Multiple Models of Systemic Lupus Erythematosus (SLE)
Abstract Number: 2587

KZR-616, a Selective Inhibitor of the Immunoproteasome, Shows a Promising Safety and Target Inhibition Profile in a Phase I, Double-Blind, Single (SAD) and Multiple Ascending Dose (MAD) Study in Healthy Volunteers
Abstract Number: 2573

Lack of CD137-CD137 Ligand Signalling Aggravates Glomerulonephritis and Reduces the Survival of Lupus-Prone B6.MRLlpr Mice
Abstract Number: 1459

Lack of Drug-Drug Interaction between Filgotinib, a JAK-1 Selective Inhibitor, and a Representative Hormonal Contraceptive Medication, Levonorgestrel/Ethinyl Estradiol
Abstract Number: 1809

Lack of Placental Transfer of Certolizumab Pegol during Pregnancy: Results from a Prospective, Postmarketing, Multicenter, Pharmacokinetic Study
Abstract Number: 148

Lack of Screening By Rheumatologists and Primary Care Physicians for Childhood Sexual Abuse in Patients with Fibromyalgia-Depression Overlap: An Unrecognized Crisis?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].